14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
XBI vs IBB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, iShares Biotechnology ETF (IBB) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (46.9/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XBI trades at $140.18 (N/M Forward P/E, N/A operating margin) versus IBB at $199.54 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. IBB 46.9/100 HOLD), IBB captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: XBI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5); meanwhile IBB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBI vs IBB. Trailing 12-month operating profitability (XBI N/A vs IBB N/A) and valuation multiples (XBI N/M vs IBB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XBI vs IBB Key Questions & Quantitative Answers
As of Nov 20, 2026, iShares Biotechnology ETF (IBB) captures the overall head-to-head institutional edge over SPDR S&P Biotech ETF (XBI) on higher Unified Composite conviction (46.9/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 2–1 (led by composite factor balance), while XBI wins 1–0 across the 6-pillar growth and valuation breakdown. XBI trades at $140.18 (N/M Forward P/E, N/A operating margin) versus IBB at $199.54 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XBI currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. IBB 46.9/100 HOLD), IBB captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: XBI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5); meanwhile IBB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XBI and IBB split Growth & Scale metrics: XBI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IBB at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XBI generates N/A in USD-normalized revenue versus N/A for IBB. In operating R&D and SG&A reinvestment, XBI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBB.
XBI and IBB trade at balanced relative valuation multiples. XBI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IBB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XBI (N/A ROE) versus IBB (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XBI carries 58.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.17β · 38% Vol realized risk). By comparison, IBB carries 22.9% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 29% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.